A Chemical Screen Probing the Relationship between Mitochondrial Content and Cell Size by Kitami, Toshimori et al.
A Chemical Screen Probing the Relationship between
Mitochondrial Content and Cell Size
Toshimori Kitami
1,2,3, David J. Logan
1, Joseph Negri
1, Thomas Hasaka
1, Nicola J. Tolliday
1,
Anne E. Carpenter
1, Bruce M. Spiegelman
4, Vamsi K. Mootha
1,2,3*
1Broad Institute, Cambridge, Massachusetts, United States of America, 2Department of Systems Biology, Harvard Medical School, Boston, Massachusetts, United States of
America, 3Department of Molecular Biology, Massachusetts General Hospital, Boston, Massachusetts, United States of America, 4Department of Cell Biology, Dana-Farber
Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States of America
Abstract
The cellular content of mitochondria changes dynamically during development and in response to external stimuli, but the
underlying mechanisms remain obscure. To systematically identify molecular probes and pathways that control
mitochondrial abundance, we developed a high-throughput imaging assay that tracks both the per cell mitochondrial
content and the cell size in confluent human umbilical vein endothelial cells. We screened 28,786 small molecules and
observed that hundreds of small molecules are capable of increasing or decreasing the cellular content of mitochondria in a
manner proportionate to cell size, revealing stereotyped control of these parameters. However, only a handful of
compounds dissociate this relationship. We focus on one such compound, BRD6897, and demonstrate through secondary
assays that it increases the cellular content of mitochondria as evidenced by fluorescence microscopy, mitochondrial
protein content, and respiration, even after rigorous correction for cell size, cell volume, or total protein content. BRD6897
increases uncoupled respiration 1.6-fold in two different, non-dividing cell types. Based on electron microscopy, BRD6897
does not alter the percent of cytoplasmic area occupied by mitochondria, but instead, induces a striking increase in the
electron density of existing mitochondria. The mechanism is independent of known transcriptional programs and is likely to
be related to a blockade in the turnover of mitochondrial proteins. At present the molecular target of BRD6897 remains to
be elucidated, but if identified, could reveal an important additional mechanism that governs mitochondrial biogenesis and
turnover.
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Introduction
The cellular abundance of mitochondria varies across organ-
isms, organs, and in response to environmental cues. Kleiber [1]
noted that the total amount of mitochondria in a given organism,
as measured by whole body respiration, scales across organisms
according to a power law of the body mass. Mitochondria abound
in the heart, brown fat, and skeletal muscle [2], while mature red
blood cells are devoid of mitochondria. Changes in energy
demand [3] and particular signaling events [4,5] can modulate
mitochondrial content. Moreover, the cellular content of mito-
chondria, based on electron microscopy, changes in proportion to
cell size throughout the cell cycle [6].
While variation in mitochondrial content across these lengths
and time scales has been documented, the underlying mechanisms
remain to be fully elucidated. It has been studied most extensively
at the transcriptional level. Mitochondrial content in many cell
types is enhanced through a carefully studied transcriptional
program involving the PGC-1 family of coactivators [7–9] that
partner with key transcription factors ERRA [10,11], NRF1
[12,13], and NRF2 (GABP) [14–16]. With the exception of these
transcriptional programs, little is known about the molecular
mechanisms governing the cellular content of mitochondria.
To systematically identify molecular probes and new pathways
that regulate mitochondrial content, we performed an image-
based screen across 28,786 compounds. Hundreds of compounds
elevated mitochondrial content in a manner proportionate to cell
size. However, a few compounds, including BRD6897, were able
to elevate mitochondrial content without altering cell size.
BRD6897 increased the density of mitochondria and respiration
independent of known transcriptional mechanisms. The screening
approach and this tool compound could prove useful in
discovering new pathways that control the cellular content of
mitochondria.
Results and Discussion
To monitor changes in cellular mitochondrial content, we
developed a fluorescent image-based assay (Figure 1) in human
umbilical vein endothelial cells (HUVECs). These primary human
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ideal for image analysis. Hoechst nuclear stain was used to identify
each nucleus in the images, the F-actin stain phalloidin was used to
define the boundary of the cell, and MitoTracker Deep Red was
used to monitor changes in mitochondrial content. For each cell,
total MitoTracker intensity as well as that cell’s cytoplasmic area
were measured. For a given image, median values were calculated
from the population of cells.
We screened in biological duplicate 28,786 small molecules
treated for a three-day period (Figure 2 A). Surprisingly, we found
that hundreds of compounds increased MitoTracker intensity
(Figure 2 B) on a per cell level. On closer inspection, however,
most of these compounds also increased cell size in proportion to
the fold increase in mitochondrial content (Figure 2 A). These
compounds included many of the known bioactives including
previously identified enhancers of mitochondrial content [17,18]
such as microtubule modulators paclitaxel (Figure 2 D, E) and
deoxysappanone. The screening results support and extend the
original observations of Posakony et al. [6] that cell size and
mitochondrial content are strongly coupled and suggest that
mechanisms regulating cell size also influence mitochondrial
content.
Hence, we became particularly interested in molecules capable
of dissociating the relationship between cell size and mitochondrial
content, as they could potentially reveal novel mechanisms
controlling mitochondrial content (Figure 2 C). The 160 highest
scoring compounds that increased MitoTracker intensity after
normalizing for cell size were selected for secondary assays. The
assays consisted of immunofluorescence assays for mitochondrial
protein content and qPCR assays for mitochondrial DNA
(mtDNA) copy number. Ten highest scoring compounds from
each secondary assay were promoted for oxygen consumption
assays to ensure that elevations in mitochondrial content
corresponded to an increase in functional respiratory capacity.
Of the 20 compounds tested, three compounds (BRD6897,
BRD6445, BRD1108) showed statistically significant increases in
uncoupled respiration (Figure S1).
We chose to focus on one of these three compounds, namely
BRD6897 (Figure 3 A), as it imparted the greatest, dose-dependent
increase in uncoupled respiration (Figure S2). BRD6897 comes
from a kinase inhibitor-biased library of compounds that are
predicted to bind the ATP ligand site of kinases, though its specific
target is not known. The binding ability of BRD6897 to a panel of
442 kinases [19] was tested using 10 mM compound concentration
but failed to reveal any significant binding. The result suggests that
BRD6897 does not have strong affinity for a range of kinases often
observed with known kinase inhibitors [19,20]. In our cells, a
10 mM dose of BRD6897 induces a 1.55 fold increase in
uncoupled respiration (Figure 3 C). Additional screening of 36
structural analogs of BRD6897 not present in the initial screening
collection failed to reveal more potent inducers of mitochondrial
content (Figure S3). An increase in uncoupled respiration with
BRD6897 is detectable by two days of treatment (Figure S4 A),
plateaus after three days of treatment (Figure S4 B), and is partially
reversible after removal of the compound for three days (Figure S4
C). The increase in respiration is robust to the normalization
scheme used. BRD6897 increases respiration when normalized to
total cell number [1.35-fold], total cell volume [1.46-fold], or total
cellular protein [1.57-fold]. The compound is toxic in dividing
cells but is capable of enhancing uncoupled respiration in other
non-dividing cells. For example, it induces a 1.60-fold elevation in
uncoupled respiration in confluent 3T3-L1 preadipocytes at a dose
of 10 mM (Figure S5).
We next sought to identify the cellular pathways through which
BRD6897 might be acting. If it is acting via the known
transcriptional pathways of mitochondrial biogenesis [8], we
would expect concomitant elevations in both nuclear DNA and
mitochondrial DNA (mtDNA) encoded OXPHOS genes. In
addition, mtDNA copy number itself as well as OXPHOS protein
level should increase. Contrary to this expectation, BRD6897
shows no significant elevation in nuclear DNA encoded OXPHOS
gene expression while mtDNA encoded OXPHOS gene expres-
sion is increased (Figure 3 F). Moreover, BRD6897 actually
reduces mtDNA copy number (Figure 3 E) while elevating
OXPHOS protein content (Figure 3 D). These findings indicate
that BRD6897 is not acting through the canonical transcriptional
programs and suggests that other mechanisms are at play.
To examine the mechanisms responsible for the increase in
uncoupled respiration, we studied the morphology of mitochon-
dria by electron microscopy. The proportion of cytoplasm area
occupied by mitochondria in BRD6897-treated HUVEC did not
differ significantly from DMSO-treated HUVEC (Figure 4 A).
This is in contrast to the increase in mitochondrial area observed
during PGC-1a mediated mitochondrial biogenesis [8]. Instead,
mitochondria in BRD6897-treated HUVEC appeared more
electron dense compared to mitochondria in DMSO-treated
Figure 1. An image-based assay for mitochondrial content and cell size.
doi:10.1371/journal.pone.0033755.g001
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mitochondria. We next examined whether OXPHOS protein
synthesis or degradation was altered upon BRD6897 treatment
using pulse-chase labeling. BRD6897 did not increase the rate of
cytochrome C synthesis (Figure S6, left). However, BRD6897
slowed the rate of cytochrome C degradation (Figure S6, right)
suggesting that mitochondrial protein turnover is partially
inhibited by BRD6897. Therefore, BRD6897 does not appear to
induce mitochondrial biogenesis via transcriptional programs, but
perhaps through a mechanism involving decreased mitochondrial
protein turnover.
In summary we have performed a high-throughput, high-
content microscopy assay that reveals a stereotyped, coordinated
control of mitochondrial content and cell size preserved across
hundreds of small molecule perturbations. Given that growth
factors [21,22] such as VEGF and downstream mitogenic signals
such as myc [22,23] are known to induce mitochondrial biogenesis
as well as stimulate cell growth, these signals may be responsible
for ensuring the strong coupling between mitochondrial content
and cell size. Importantly, we identified a handful of molecules
that are unique in their ability to disrupt the strong relationship
between mitochondrial content and cell size. One such compound,
BRD6897, increases cellular mitochondrial content on the basis of
microscopy, protein content, and respiration in two different non-
dividing cell types. It does not appear to activate the known
transcriptional programs of mitochondrial biogenesis, but rather,
appears to influence mitochondrial content perhaps by modulating
protein turnover. At present the precise molecular target of
BRD6897 remains to be elucidated, but if identified, could reveal
an important new pathway, that together with transcriptional
programs of mitochondrial biogenesis, would serve to regulate
mitochondrial content.
Figure 2. The relationship between mitochondrial content and cell size revealed through 28,786 chemical perturbations. (A)
MitoTracker intensity per cell versus cytoplasm area per cell for each compound relative to DMSO, reported as the median value across the
population of cells in an image. The median values were averaged per compound across biological duplicates and represented by a dot. (B)
Frequency distribution of (MitoTracker intensity) per cell. (C) Frequency distribution of (MitoTracker intensity/cytoplasm area) per cell. (D) MitoTracker
intensity versus cytoplasm area for 4.6 mM paclitaxel treatment. Each dot represents one cell in an image. (E) Images of DMSO and paclitaxel treated
HUVEC stained with Hoechst (blue) and MitoTracker (red). White lines define derived cell boundaries. Scale bar: 50 mm.
doi:10.1371/journal.pone.0033755.g002
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Cell culture
Human umbilical vein endothelial cells (HUVEC) from a single
donor was obtained from Lonza and grown in EGM2 media
(Lonza). All experiments were performed between passage 3 and
6. 3T3-L1 preadipocyte was grown in DMEM with 4 mM
glutamine and 1 mM sodium pyruvate supplemented with 10%
calf serum and penicillin/streptomycin. All cells were grown at
37uCi n5 %C O 2.
Compound collection
Compound libraries were assembled from the following
suppliers. Bioactives: 1920 compounds from Biomol ICCB
Bioactive, Neurotransmitter, and Kinase Inhibitor libraries, the
MicroSource Spectrum library, and Prestwick Chemical library.
Natural products: 1600 compounds from AnalytiCon’s MEGx
collection excluding unpurified and partially purified extracts.
Commercial compounds: 3520 drug-like libraries from TimTec,
Maybridge, and ChemDiv. Kinase inhibitor biased compounds:
11520 compounds from ChemBridge’s KINA set. Chemical
biology production libraries: 10226 compounds from diversity-
oriented synthesis efforts at the Broad Institute Chemical Biology
Platform. All compounds were previously tested for purity and
identity using liquid chromatography-mass spectrometry (LC-MS).
Image-based primary screen
HUVEC were seeded in 384-well CellBIND black-wall plate
(Corning) at 4000 cells per well in 50 mL of EGM2 and allowed to
reach confluence for two days. EGM2 was replaced and 100 nL of
Figure 3. Effects of BRD6897 on mitochondrial content, gene expression, and physiology. (A) Chemical structure of BRD6897. (B) Images
of DMSO- and BRD6897-treated HUVEC stained with Hoechst (blue) and MitoTracker (red). Scale bar: 50 mm. (C) Basal and uncoupled respiration of
HUVEC treated for 3-days with 10 mM BRD6897. (D) Cytochrome C protein level detected by ELISA normalized to total protein content after 3-day
treatment with 10 mM BRD6897. (E) Ratio of mitochondrial to nuclear DNA copy number after 3-day treatment with 10 mM BRD6897. (F) qPCR
analysis of OXPHOS genes upon 3-day BRD6897 treatment. mtOXPHOS (mt-CoI) and nuclear encoded OXPHOS genes (Cycs, Cox5b) were profiled. As
a positive control for activation of mitochondrial biogenesis program, PGC-1a was over-expressed for three days and compared to GFP over-
expression for three days. Changes in treatment relative to control were analyzed with unpaired t-test. * p,0.05, ** p,0.01, *** p,0.001.
doi:10.1371/journal.pone.0033755.g003
Figure 4. Changes in mitochondrial ultrastructure upon 3-day 10 mM BRD6897 treatment. (A) Plot of % cytoplasmic area occupied by
mitochondria based on 10 replicate electron microscopy (EM) images per treatment. (B) Representative EM images of DMSO- and BRD6897-treated
HUVEC. Scale bar: 500 nm.
doi:10.1371/journal.pone.0033755.g004
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final concentration. After 3-day incubation with compounds, cells
were treated with 200 nM MitoTracker Deep Red (Invitrogen) for
30 minutes at 37uCi n5 %C O 2, fixed in 4% paraformaldehyde for
20 minutes, permeabilized with 0.2% Triton-X (Sigma) for
5 minutes, and stained with 2 mg/mL Hoechst 33342 (Invitrogen)
and 130 nM Alexa Fluor 488 phalloidin (Invitrogen) for
30 minutes. Cells were imaged with the ImageXpress Micro
System (Molecular Devices) at 206 magnification, one site per
well, with binning of 1 and gain of 2 using laser-based focusing.
Images were captured using a DAPI filter (387/11 nm Ex, 447/
60 nm Em) for 50 msec, Cy5 filter (628/40 nm Ex, 692/40 nm
Em) for 1000 msec, and GFP filter (472/30 nm Ex, 520/35 nm
Em) for 750 msec for Hoechst 33342, MitoTracker Deep Red,
and AlexaFluor 488 phalloidin respectively. All compounds were
screened in duplicate and each day of screening contained DMSO
negative control plates.
Image processing
All images were processed using CellProfiler [24]. Raw images
were first corrected for uneven illumination per channel per plate.
For MitoTracker signal, a background threshold was applied using
Otsu three-class thresholding. For each well, nuclei were first
identified using Hoechst stain. Then cell boundaries were
identified using phalloidin stain using the propagation algorithm
[25] where distances between nuclei are used to assist in
identifying cell boundary. The nucleus region was masked from
the whole cell to define the cytoplasm. Nucleus masking allowed us
to discount background MitoTracker staining in the nucleus that
could not be eliminated with background thresholding. For each
cell, total MitoTracker intensity within the cytoplasm, and
cytoplasm area, were measured. MitoTracker intensity was also
normalized to cytoplasm area for each cell. Full detail of the image
processing pipeline is available at: http://www.cellprofiler.org/
published_pipelines.shtml.
Screening data analysis
For each image, the median value of MitoTracker intensity
normalized to cytoplasm area was computed. This median value
was converted to composite Z-score as described previously [26].
To filter out chemicals that were toxic, we selected out wells with
cell counts that were less than 40 cells per image, corresponding to
about 30% of average cell count in negative control DMSO wells.
Compounds with Z-score greater than 1.98 (p,0.05) were
manually examined to filter out false hits that arise from staining
artifacts or errors in cell segmentation. The top 160 compounds
that passed filtering were run on LC-MS to ensure purity and
identity of hit compounds, and re-plated into cherry pick plates for
high-throughput secondary assays.
Immunofluorescence-based secondary assay
HUVEC were treated with 2 mg/mL ATP synthase subunit
alpha monoclonal antibody (MitoSciences) and 2 mg/mL Alexa-
Fluor 647 anti-mouse IgG2b (Invitrogen) according to manufac-
turer’s immunocytochemistry protocol. Images were analyzed as
primary assay and top 10 compounds were nominated for oxygen
consumption assay. Additional details are in methods S1.
mtDNA copy number secondary assay
DNA was prepared from HUVEC using HotSHOT protocol
[27], diluted in water 1:64, and qPCR was performed using
mtND2 (mtDNA encoded) and Alu (nuclear DNA encoded)
probes using TaqMan reagents (Applied Biosystems). Top 10
compounds with increased mtDNA/nuDNA ratio were nominat-
ed for oxygen consumption assay. Additional details are in
methods S1.
Oxygen consumption assay
Oxygen consumption rates (OCR) were measured with XF24
Analyzer (Seahorse Biosciences) using manufacturer’s protocol
[28] for basal OCR followed by incubation with 1 mM carbonyl
cyanide 3-chlorophenylhydrazone (CCCP) for uncoupled OCR.
Basal and uncoupled OCRs per well were averaged across
replicate measurements and then normalized to total protein
content. Compounds that showed statistically significant increase
in uncoupled respiration were re-purchased from suppliers, re-
tested, and used for subsequent studies. BRD6897 (PubChem ID:
1252659, ChemBridge catalog #: 7930518), BRD6445 (PubChem
ID: 2914607, ChemBridge catalog #: 6804267), BRD1108
(PubChem ID: 2213867, ChemBridge catalog #: 7852208).
Additional details are in methods S1.
Cell counting, cell volume, and total protein content
measurement
Cell count and cell volume were determined by Scepter cell
counter (Millipore) according to manufacturer’s instruction. Total
protein content was quantified with Pierce BCA Protein Assay Kit
(Thermo Scientific) according to manufacturer’s instruction.
Cytochrome C ELISA
Cytochrome C from total cell lysate was detected using human
cytochrome C Quantikine ELISA kit (R&D Systems) using
manufacturer’s instruction and normalized to total protein
content.
mtDNA copy number assay
DNA was extracted using DNeasy kit (Qiagen) and the same
qPCR probes were used as the high-throughput mtDNA assay.
Real-time PCR assay
Total RNA was extracted with RNeasy Mini kit (Qiagen) and
genomic DNA was digested using RNase-Free DNase (Qiagen).
200 ng of total RNA was reverse transcribed using TaqMan
reverse transcription reagents (Applied Biosystems) with random
hexamers. The relative quantity of cDNA was measured using
TaqMan universal PCR mastermix (Applied Biosystems) using
following primer/probes: Cox5b (Hs00426948_m1), Cycs
(Hs01588974_g1), mt-CoI (Hs02596864_g1), Actb (4352935).
Transmission electron microscopy
HUVEC were prepared for electron microscopy as before [29]
and imaged at 23,0006. Cytoplasm area and mitochondrial area
were analyzed manually with Image J software [30]. Additional
details are in methods S1.
Supporting Information
Figure S1 Three compounds that increase uncoupled
respiration even after correcting for cell size. HUVEC
were treated for 3-days with 10 mM of BRD6897, 10 mMo f
BRD6445 or 20 mM of BRD1108 with DMSO as a negative
control. Ten biological replicates per treatment group are
represented by dots. Fold change is indicated in the graph.
Differences between DMSO and compound treatment were
determined by t-test. *** p,0.001.
(TIF)
Screen for Mitochondrial Content and Cell Size
PLoS ONE | www.plosone.org 5 March 2012 | Volume 7 | Issue 3 | e33755Figure S2 Impact of BRD6897 on uncoupled respira-
tion. HUVEC were treated for 3-days with either DMSO
negative control or BRD6897 at 5 mM, 10 mM, and 20 mM
concentration. Ten biological replicates per treatment group are
represented by dots. Fold change is indicated in the graph.
Differences between DMSO and BRD6897 were determined by t-
test. ** p,0.01, *** p,0.001.
(TIFF)
Figure S3 Screening structural analogs of BRD6897. 36
commercially available analogs of BRD6897 were screened using
the primary assay described in Figure 1. Four analogs that showed
significant MitoTracker intensity normalized to cytoplasm area
were followed up with respiration measurements at 5 mM and
20 mM concentration. Activities of analogs based on uncoupled
respiration are described as percent of BRD6897 uncoupled
respiration.
(TIFF)
Figure S4 Time dependent effects of BRD6897 treat-
ment on respiration. (A) Changes in basal and uncoupled
respiration were measured after 0-day, 1-day, 2-day, and 3-day
incubation with 10 mM BRD6897. All cells were in culture for the
same 3-day duration with addition of BRD6897 at appropriate
time points. Five biological replicates were tested. (B) Changes in
basal and uncoupled respiration were measured after 0-day, 3-day,
and 6-day incubation with 10 mM BRD6897. All cells were in
culture for the same 6-day duration with addition of BRD6897 at
appropriate time points. Media were changed at day 3. Six or
eight biological replicates were tested as represented by dots. (C)
Changes in basal and uncoupled respiration were measured after
6-day DMSO incubation (untreated), 3-day DMSO incubation
followed by 3-day 10 mM BRD6897 incubation (treated), or 3-day
10 mM BRD6897 incubation followed by 3-day DMSO incuba-
tion (washout). Cells were washed with media 3-times on day 3.
Six or eight biological replicates were tested as represented by dots.
Differences between DMSO and BRD6897 treatment groups
were determined by ANOVA with Bonferroni’s multiple compar-
ison test. * p,0.05, ** p,0.01, *** p,0.001.
(TIFF)
Figure S5 Basal and uncoupled respiration in confluent
3T3-L1 preadipocytes upon BRD6897 treatment for 3
days. Differences between DMSO and BRD6897 treatment
groups were determined by ANOVA with Bonferroni’s multiple
comparison test. * p,0.05, ** p,0.01, *** p,0.001.
(TIFF)
Figure S6 Changes in mitochondrial protein turnover
upon BRD6897 treatment as detected by pulse-chase
labeling. HUVEC were treated with either DMSO or 10 mM
BRD6897 for 2 days. Cells were then ‘‘pulse’’ labeled with
methionine/cysteine for 2, 4, or 6 hours (left panel). Following
6 hours of labeling, the label was ‘‘chased’’ for 1, 3, or 6 days (right
panel). Cytochrome C from protein lysate was immunoprecipitat-
ed and run on an SDS-PAGE gel.
(TIFF)
Methods S1 Additional details for secondary assays, oxygen
consumption assay, transmission electron microscopy, and pulse-
chase labeling and immunoprecipitation.
(DOC)
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